AIDS and Behavior

, Volume 23, Issue 10, pp 2741–2748 | Cite as

Interest in Pre-exposure Prophylaxis (PrEP) for HIV is Limited Among Women in a General Obstetrics & Gynecology Setting

  • Tess Carley
  • Emma Siewert
  • Amber NareshEmail author
Original Paper


Pre-exposure prophylaxis (PrEP) is an important tool for reducing the risk of HIV acquisition, but identifying eligible and interested female patients remains difficult. We collected 144 surveys at urban Obstetrics & Gynecology clinics in Louisiana to assess interest in PrEP. Study participants were predominantly African–American (61.8%) and 45.1% had incomes of less than $20,000 per year. 84.7% of participants estimated their risk of HIV acquisition to be low. Initial interest in PrEP was moderate at 37.5% of the population. Number of partners, condom use, and self-perceived risk of HIV acquisition were associated with initial interest. After receiving more information about side effects and compliance requirements, only four of 144 (7.8% of initially interested, 2.8% of total) women remained interested in using PrEP. Concern about side effects was the major barrier to persistent interest. Further study is needed to determine how best to identify PrEP candidates in Obstetrics & Gynecology settings.


Pre-exposure prophylaxis HIV infections Surveys and questionnaires Ambulatory care facilities 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in this study were in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Centers for Disease Control and Prevention. HIV Surveillance Report, 2017; vol. 29. Published November 2018. Available from: Accessed 9 Jan 2019.
  2. 2.
    Centers for Disease Control and Prevention. HIV among women. Available from: Accessed 5 Dec 2018.
  3. 3.
    AIDSVu. Mapping PrEP: First Ever Data on PrEP Users Across the U.S. Available from: Accessed 4 Jan 2019.
  4. 4.
    Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. Published March 2018.
  5. 5.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRefGoogle Scholar
  6. 6.
    McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53.CrossRefGoogle Scholar
  7. 7.
    Molina JM, Capitant C, Spire B, Pialoux G, Cotte J, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J of Med. 2015;373(23):237–46.CrossRefGoogle Scholar
  8. 8.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J of Med. 2012;367(5):399–410.CrossRefGoogle Scholar
  9. 9.
    Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423.CrossRefGoogle Scholar
  10. 10.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefGoogle Scholar
  11. 11.
    Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefGoogle Scholar
  12. 12.
    Hanscom B, Janes HE, Guarino PD, et al. Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr. 2016;73(5):606.CrossRefGoogle Scholar
  13. 13.
    Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55–64.CrossRefGoogle Scholar
  14. 14.
    Goparaju L, Experton LS, Praschan NC, Warren-Jeanpiere L, Young MA, Kassaye S. Women want pre-exposure prophylaxis but are advised against it by their HIV-positive counterparts. J AIDS Clin Res. 2015;6(11):1–10.CrossRefGoogle Scholar
  15. 15.
    Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–10.CrossRefGoogle Scholar
  16. 16.
    Raifman JR, Schwartz SR, Sosnowy CD, et al. Brief report: pre-exposure prophylaxis awareness and use among cisgender women at a sexually transmitted disease clinic. J Acquir Immune Defic Syndr. 2019;80(1):36–9.CrossRefGoogle Scholar
  17. 17.
    Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care. 2018;30(10):1282–9.CrossRefGoogle Scholar
  18. 18.
    Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. AIDS Care. 2018;30(1):9–17.CrossRefGoogle Scholar
  19. 19.
    McMahan V, Martin A, Garske L, Baeten J, Banta-Green C, Stekler J. Knowledge about PrEP among MSM and Trans Methamphetamine Users in Seattle. Conference on Retroviruses and Opportunistic Infections 2017, Abstract # 967. Available at: Accessed 10 Jan 2019.
  20. 20.
    Adefuye AS, Abiona TC, Balogun JA, Lukobo-Durrell M. HIV sexual risk behaviors and perception of risk among college students: implications for planning interventions. BMC Public Health. 2009;9:281.CrossRefGoogle Scholar
  21. 21.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at AdultandAdolescentGL.pdf. Accessed 11 Jan 2019.
  22. 22.
    Calabrese SK, Dovidio JF, Tekeste M, Taggart T, Galvao RW, Safon CB, et al. HIV pre-exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend planned parenthood. J Acquir Immune Defic Syndr. 2018;79(1):46–53.CrossRefGoogle Scholar
  23. 23.
    Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S. Stigma, partners, providers and costs: potential barriers to PrEP uptake among US Women. J AIDS Clin Res. 2017;8(9):730.CrossRefGoogle Scholar
  24. 24.
    Hoffman S, Guidry JA, Collier KL, et al. A clinical home for pre exposure prophylaxis (PrEP): diverse health care providers’ perspectives on the “Purview Paradox”. J Int Assoc Provid AIDS Care. 2016;15(1):59–65.CrossRefGoogle Scholar
  25. 25.
    Preexposure prophylaxis for the prevention of human immunodeficiency virus. Committee Opinion No. 595. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:1133–6.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of MedicineTulane UniversityNew OrleansUSA
  2. 2.Department of Obstetrics and GynecologyTulane UniversityNew OrleansUSA

Personalised recommendations